Search Results

The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies to list on the public market with a bundle of cash to operate on.

Intensity Therapeutics, Inc. announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer in 54 patients in Switzerland and selected countries in Europe.

Medivir AB announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.

ObsEva SA announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing.

The company Swiss Advanced Vision has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.

Addex Therapeutics announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.